First Western Trust Bank Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Western Trust Bank raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 514 shares of the biopharmaceutical company’s stock after purchasing an additional 51 shares during the quarter. First Western Trust Bank’s holdings in Regeneron Pharmaceuticals were worth $540,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Quent Capital LLC raised its position in shares of Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 19 shares in the last quarter. Covestor Ltd lifted its holdings in Regeneron Pharmaceuticals by 7.4% in the first quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 14 shares during the period. O Shaughnessy Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 17.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock worth $6,660,000 after acquiring an additional 1,030 shares during the period. UniSuper Management Pty Ltd boosted its stake in Regeneron Pharmaceuticals by 174.1% during the 1st quarter. UniSuper Management Pty Ltd now owns 2,409 shares of the biopharmaceutical company’s stock valued at $2,319,000 after purchasing an additional 1,530 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $36,575,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 3.3 %

Regeneron Pharmaceuticals stock opened at $756.81 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $753.69 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $83.17 billion, a PE ratio of 18.73, a P/E/G ratio of 2.86 and a beta of 0.15. The firm’s 50 day moving average price is $985.21 and its two-hundred day moving average price is $1,034.89.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Evercore ISI reduced their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.48% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.